Presentations
1. Erkan D, Yazici Y, Peterson M, Sammaritano L, Lockshin MD. A cross sectional study of oral contraceptive and estrogen replacement therapy use in the antiphospholipid syndrome. Annals of the Rheumatic Diseases 2002;61(S1):220 (Presented at 2002 EULAR meeting) 2. Erkan D, Yazici Y. Combination treatment with mycophenolate mofetil (MM) and intravenous immunoglobulin (IVIG) in cyclophosphamide-resistant lupus nephritis. Annals of the Rheumatic Diseases 2002;61(S1):391 (Presented at 2002 EULAR meeting) 3. Erkan D, Yazici Y, Harrison MJ, Fields T, Paget SA. Treatment preferences for the initial presentation of rheumatoid arthritis (RA): Are physicians becoming more aggressive? Annals of the Rheumatic Diseases 2002;61(S1):344 (Presented at 2002 EULAR meeting) 4. Erkan D, Yazici Y, Rusche W, Daud U, Moore TL, Schwartzman S, Ince A. Real-world experience with infliximab in the treatment of non-rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2002;61(S1):465 (Presented at 2002 EULAR meeting) 5. Yazici Y, Erkan D. Genetic testing in the diagnosis of familial Mediterranean fever: Atypical clinical presentations in the setting of V726A mutations in the heterozygous state. Annals of the Rheumatic Diseases 2002;61(S1):248 (Presented at 2002 EULAR meeting) 6. Yazici Y, Erkan D, Kulman I, Harrison MJ, MS, Magid SK. Total joint replacement in SLE patients: Perioperative management, complications, and outcomes in a tertiary care center. Annals of the Rheumatic Diseases 2002;61(S1):315 (Presented at 2002 EULAR meeting) 7. Yazici Y, Erkan D, Kulman I, Harrison MJ, Schwartzman S. Infliximab for the treatment of rheumatoid arthritis: Do outcomes at 1 year in the "real world" match clinical trials' data? Annals of the Rheumatic Diseases 2002;61(S1):196 (Presented at 2002 EULAR meeting)
|
